Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from AstraZeneca

Pay gap widens as UK bosses get 130 times average worker’s salary

In its final report the High Pay Centre says the median remuneration of a FTSE 100 CEO has risen to a record £5.06m

The Guardian - UK

Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bn

Alembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug, which is a generic equivalent of Lynparza. Alembic will distribute the product while NATCO Pharma will manufacture the tablets. The product addresses a significant market opportunity, estimated at USD 1.4…

The Economic Times

AstraZeneca to license lung cancer drug from China's Dizal Pharmaceutical

Dizal Pharmaceutical shares rose significantly after announcing a major drug rights deal. AstraZeneca will pay $600 million upfront for global rights to Sunvozertinib. This targeted treatment addresses a specific genetic mutation in lung cancer patients. The agreement includes potential future payments tied to development and sales. This collaboration aims to…

The Economic Times

From analysis to the latest developments in health,
read the most diverse news in one place.

The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions

Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals.

MarketBeat

AstraZeneca Shares Sink After Heart Drug Trial Miss. Rare Clinical Setback Tests Investor Confidence

AstraZeneca shares fell sharply Thursday after the pharmaceutical giant reported that its experimental use of Wainua failed to achieve the primary endpoint in a late-stage clinical trial for a rare heart disease.

International Business Times

FTSE 100 held back by AstraZeneca trial setback

The FTSE 100 closed down 16.59 points at 10,472.45.

Evening Standard

AstraZeneca sees stock market value slump by more than £20bn after drug setback

The FTSE 100 firm found the Wainua drug failed to meet a goal to reduce deaths related to heart disease.

Evening Standard

Read news from The Economist, FT, and more,
with one subscription

Global Market: European shares rebound as tech stocks recover; investors assess Middle East developments

European stock markets traded higher on Thursday, recovering from previous losses. Technology shares led the gains, driven by renewed interest in artificial intelligence demand. Oil prices eased despite ongoing geopolitical uncertainty in the Middle East region. Spanish equities outperformed regional peers after trade-related tensions eased. AstraZeneca shares tumbled significantly after…

The Economic Times

AstraZeneca shares slide after Ionis-partnered drug fails late-stage heart disease trial

AstraZeneca shares fell after Wainua failed a key trial. The drug did not reduce cardiovascular deaths or heart problems. Wainua showed no effect in patients already on stabilizer therapy. A subgroup taking the drug without stabilizers showed a nominal benefit. This setback impacts a projected two billion dollar sales opportunity.

The Economic Times

Stocks mixed as weak miners weigh in muted trade

Data showed the UK construction sector remained deep in contraction during June, although the pace of decline eased slightly from May’s six-year low.

Evening Standard

FTSE 100 rises as US jobs data eases Fed rate hike fears

The FTSE 100 closed up 174.53 points, 1.7%, at 10,652.87.

Evening Standard

Global drugmakers rush to boost US presence as tariff threat looms

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Companies are investing billions in new plants and expanding existing facilities across America. These moves aim to avoid penalties and ensure supply chains remain robust. Several major pharmaceutical firms have…

The Economic Times

First-in-Class Drug Targeting Treatment-Resistant High Blood Pressure Wins FDA Approval — and Works Like No Existing Drug

FDA approved baxdrostat (Baxfendy) on May 18, 2026 as the first-ever oral aldosterone synthase inhibitor for uncontrolled and resistant hypertension. BaxHTN Phase 3 (NEJM 2025): 8.7–9.8 mmHg additional systolic blood pressure reduction added to background therapy. Here is the full story.

Medical Daily

Breast cancer and endometriosis drug Zoladex is being pulled from Australia. How will women be affected?

The vital medicine, made by AstraZeneca, will not be available from November, possibly leaving thousands of women without treatment

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

AstraZeneca daily pill shows promising weight loss results in trial

IN FULL

The Independent UK

New daily weight loss pill helps people shed 10 per cent of body weight

The pill doesn’t have the fasting requirements of many other weight loss drugs

The Economic Times

India a major growth market for Celonis, says senior exec

The Germany-based company said it already serves 260 global capability centres (GCCs) in India, counting companies such as Mercedes-Benz, Hitachi Energy and AstraZeneca as its clients, and sees a larger opportunity ahead as enterprises try to connect AI systems with operational data spread across departments and software systems.

AAP

NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History

NEW YORK, June 5, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on June 5thInvestors are reacting to the May jobs…

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Low-dose Zoladex won’t be available in Australia from November. What might that mean for you?

The drug goserelin – commonly known as Zoladex – has been a quietly crucial medicine in Australia for decades.

Pedestrian.tv

A Key Endometriosis & Breast Cancer Drug Is Being Pulled From Australia: ‘Deeply Concerned’

AstraZeneca will discontinue the Zoladex 3.6mg implant in Australia from November 2026, affecting people with breast cancer and endometriosis.

Evening Standard

Women dying of breast cancer as life-extending drug remains blocked in England

A campaign is calling for Enhertu to be made available on the NHS.

MarketBeat

Compugen Q1 Earnings Call Highlights

Compugen (NASDAQ:CGEN) said it remains on track to report interim progression-free survival data in the first quarter of 2027 from its MAIA-ovarian study, as the clinical-stage immuno-oncology company outlined first-quarter 2026 results and updates across its internal and partnered programs. On the

MarketBeat

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

MarketBeat

Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance despite a slower first-quarter sequential growth rate, pointing to access, international launches and prescriber expansion as key drivers for the rest of the year

MarketBeat

Innate Pharma Q1 Earnings Call Highlights

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.